Sharing study information by email? Is it safe? Is it secure? Is it compliant? Understand the risks (and mitigate them).
The largest collection of breached data in history has been discovered last December, according to The Guardian, comprising more than 770 million email addresses and passwords. From simple spam to intricate viruses, hacking, phishing, spoofing, or ransomware, the risks of using email in clinical trial communications are rising. But beyond obvious security risks, more liabilities are lurking.
Email is ubiquitous to our daily life and it is understandable that people think it's fine to share sensitive and confidential information by email. However the perceived security of email is a mirage. Email is too easy to misuse and lacks controls on information distribution that are standard in other mission-critical clinical trial systems.
A few reasons to reconsider your use of email:
- Rising security risks
- Prone to mistaken sharing of information
- Lacks adequate distribution controls
- Ineffective and inefficient when audited
Join clinical trial communication and technology expert Johnny Bilotta to learn the truth about the wild and scary world of email.
What you will learn:
- Become better informed about the visible and hidden liabilities of email
- Make educated judgements about how you and your team use email during your clinical activities
- Consider alternative solutions to mitigate risks
Perfect for teams in:
- Clinical Operations
- Clinical Project Management
- Quality Assurance
- Clinical Development Leadership
The Hidden Liabilities of Using Email for Clinical Trial Communications
on a single, secure and private channel
knowledge and information transfers in real-time
compliance and stay audit-ready at all times